Published in Am J Gastroenterol on May 01, 2002
Complications of hepatic chemoembolization. Semin Intervent Radiol (2006) 1.35
Current and future treatments for hepatocellular carcinoma. World J Gastroenterol (2015) 0.92
Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization. World J Gastroenterol (2014) 0.86
Cell apoptosis and regeneration of hepatocellular carcinoma after transarterial chemoembolization. World J Gastroenterol (2004) 0.86
Acute-on-chronic liver failure: terminology, mechanisms and management. Nat Rev Gastroenterol Hepatol (2016) 0.82
Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis. BMC Gastroenterol (2015) 0.79
Incidence and risk factors for radiocontrast-induced nephropathy in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization. Clin Exp Nephrol (2011) 0.79
Cancer therapy related complications in the liver, pancreas, and biliary system: an imaging perspective. Insights Imaging (2015) 0.78
Transarterial chemoembolization complicated by deteriorating hepatic function. Semin Intervent Radiol (2011) 0.75
Effects of Oral L-Carnitine on Liver Functions after Transarterial Chemoembolization in Intermediate-Stage HCC Patients. Mediators Inflamm (2015) 0.75
Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization. Clin Mol Hepatol (2016) 0.75
Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma. J Control Release (2017) 0.75
Locoregional and systemic therapy for hepatocellular carcinoma. J Gastrointest Oncol (2017) 0.75
Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology (2004) 4.12
MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest (2012) 3.46
Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology (2009) 3.42
Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Am J Psychiatry (2014) 2.88
Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol (2009) 2.56
Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys (2003) 2.25
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology (2007) 2.11
Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. Liver Int (2009) 2.09
Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol (2003) 2.08
Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol (2013) 2.08
First identification of a patient colonized with Klebsiella pneumoniae carrying blaNDM-1 in Taiwan. J Chin Med Assoc (2010) 2.05
Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology (2003) 1.92
Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology (2004) 1.78
A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol (2010) 1.77
A prospective, randomized trial of endoscopic hemoclip versus heater probe thermocoagulation for peptic ulcer bleeding. Am J Gastroenterol (2002) 1.73
Asian consensus report on functional dyspepsia. J Gastroenterol Hepatol (2012) 1.66
Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis. Liver Int (2007) 1.66
Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology (2002) 1.64
Asian consensus on irritable bowel syndrome. J Gastroenterol Hepatol (2010) 1.64
Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment. Am J Gastroenterol (2004) 1.63
Correlation and comparison of the model for end-stage liver disease, portal pressure, and serum sodium for outcome prediction in patients with liver cirrhosis. J Clin Gastroenterol (2007) 1.60
A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation. Hepatology (2006) 1.57
Is the corrected-creatinine model for end-stage liver disease a feasible strategy to adjust gender difference in organ allocation for liver transplantation? Transplantation (2007) 1.56
Spinal microglia initiate and maintain hyperalgesia in a rat model of chronic pancreatitis. Gastroenterology (2011) 1.55
Eosinophilic esophagitis in an asymptomatic Chinese. J Chin Med Assoc (2008) 1.51
Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol (2008) 1.50
Prevalence and health/social impacts of functional dyspepsia in Taiwan: a study based on the Rome criteria questionnaire survey assisted by endoscopic exclusion among a physical check-up population. Scand J Gastroenterol (2005) 1.47
Asymmetric dimethylarginine (ADMA) determines the improvement of hepatic endothelial dysfunction by vitamin E in cirrhotic rats. Liver Int (2011) 1.46
Characteristics of autoimmune hepatitis in Taiwan: the 11 years' experiences of a medical center. Zhonghua Yi Xue Za Zhi (Taipei) (2002) 1.45
Prediction of liver fibrosis in patients with chronic hepatitis B by serum markers. Hepatogastroenterology (2007) 1.43
HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene (2002) 1.43
Chronic thalidomide administration enhances vascular responsiveness to vasopressin in portal-systemic collaterals of bile duct-ligated rats. J Chin Med Assoc (2009) 1.42
Selecting a short-term prognostic model for hepatocellular carcinoma: comparison between the model for end-stage liver disease (MELD), MELD-sodium, and five cancer staging systems. J Clin Gastroenterol (2009) 1.42
Magnetic resonance angiography in reversible cerebral vasoconstriction syndromes. Ann Neurol (2010) 1.42
Green tea polyphenol decreases the severity of portosystemic collaterals and mesenteric angiogenesis in rats with liver cirrhosis. Clin Sci (Lond) (2014) 1.41
Chronic inhibition of nitric oxide increases the collateral vascular responsiveness to vasopressin in portal hypertensive rats. J Hepatol (2004) 1.41
Methimazole alleviates hepatic encephalopathy in bile-duct ligated cirrhotic rats. J Chin Med Assoc (2006) 1.40
Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer (2006) 1.40
Epidemiology of uninvestigated and functional dyspepsia in Asia: facts and fiction. J Neurogastroenterol Motil (2011) 1.39
Loss of sympathetic coordination appears to delay gastrointestinal transit in patients with spinal cord injury. Dig Dis Sci (2004) 1.39
Sepsis worsening vascular hyporeactivity of the superior mesenteric artery in portal vein-ligated rats. J Chin Med Assoc (2010) 1.39
Effects of norepinephrine and acetylcholine on portal-systemic collaterals of common bile duct-ligated cirrhotic rat. J Gastroenterol Hepatol (2005) 1.38
Ghrelin gene products and the regulation of food intake and gut motility. Pharmacol Rev (2009) 1.38
Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg (2003) 1.35
Life-threatening hemobilia caused by hepatic artery pseudoaneurysm: a rare complication of chronic cholangitis. World J Gastroenterol (2003) 1.32
Seroprevalence of antibodies to pandemic (H1N1) 2009 influenza virus among hospital staff in a medical center in Taiwan. J Chin Med Assoc (2010) 1.32
Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer (2010) 1.30
Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis. CMAJ (2011) 1.30
A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery. World J Surg (2011) 1.29
Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis. Ann Surg Oncol (2011) 1.28
Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk. Hepatology (2003) 1.28
Irritable bowel syndrome and negative appendectomy: a prospective multivariable investigation. Gut (2007) 1.23
Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology (2006) 1.22
The -251T allele of the interleukin-8 promoter is associated with increased risk of gastric carcinoma featuring diffuse-type histopathology in Chinese population. Clin Cancer Res (2005) 1.22
Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. Int J Epidemiol (2005) 1.16
Spider angiomas in patients with liver cirrhosis: role of vascular endothelial growth factor and basic fibroblast growth factor. World J Gastroenterol (2003) 1.15
Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. Cancer Causes Control (2009) 1.14
Validation of Rome II criteria for functional gastrointestinal disorders by factor analysis of symptoms in Asian patient sample. J Gastroenterol Hepatol (2003) 1.12
Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol (2010) 1.12
Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol (2007) 1.10
Asian consensus report on functional dyspepsia. J Neurogastroenterol Motil (2012) 1.09
Practical difficulties in the management of hepatitis B in the Asia-Pacific region. J Gastroenterol Hepatol (2004) 1.09